Consistency of Extended-Release Niacin/Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups

Author： Bays Harold E.  

Publisher： Adis International

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.12, Iss.3, 2012-06, pp. : 197-206

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aggressive statin therapy goals needed to drive down apoB levels

By  

Inpharma, Vol. 1, Iss. 1652, 2008-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?

By Sahebkar Amirhossein   Watts Gerald  

Cardiovascular Drugs and Therapy, Vol. 27, Iss. 6, 2013-12 ,pp. : 559-567

Springer Publishing Company

Access to resources Recommend Favorite

Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease

By Martiskainen Henna  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 7, 2013-10 ,pp. : 781-794

Informa Healthcare

Access to resources Recommend Favorite

Apo A-1 Mimetic Peptides as Atheroprotective Agents in Murine Models

By  

Current Drug Targets, Vol. 9, Iss. 3, 2008-03 ,pp. : 204-209

Bentham Science Publishers

Access to resources Recommend Favorite

Extended-Release Niacin (Nicotinic Acid)/Laropiprant

By Perry Caroline M.  

Drugs, Vol. 69, Iss. 12, 2009-08 ,pp. : 1665-1679

Adis International

Access to resources Recommend Favorite